Themis Bioscience, a biopharmaceutical company focused on immunomodulation therapies for infectious diseases and cancer, announced today that the United States Food and Drug Administration (FDA) has granted...

Themis Bioscience and CEPI – the Coalition for Epidemic Preparedness Innovations – announced today  a partnership under which Themis will provide advanced vaccine development and manufacturing for...

PRESS RELEASE A prophylactic vaccine candidate against Chikungunya fever, developed by the Austrian biotech company Themis Bioscience GmbH induces a significant neutralizing immune response and was also...